Ilya Goldshleger Sells 3,100 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total value of $142,228.00. Following the completion of the sale, the insider now owns 42,246 shares in the company, valued at approximately $1,938,246.48. The trade was a 6.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, November 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total value of $139,500.00.
• On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The shares were sold at an average price of $46.00, for a total value of $224,250.00.
• On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total value of $139,500.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The shares were sold at an average price of $46.13, for a total transaction of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total transaction of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total transaction of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total transaction of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total value of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total value of $154,318.00.

RxSight Stock Up 0.7 %

RXST opened at $46.40 on Thursday. The business has a 50 day moving average price of $49.00 and a two-hundred day moving average price of $52.48. RxSight, Inc. has a 52 week low of $28.88 and a 52 week high of $66.54. The company has a market cap of $1.87 billion, a PE ratio of -55.78 and a beta of 1.19.

Institutional Investors Weigh In On RxSight

Several hedge funds have recently modified their holdings of RXST. RA Capital Management L.P. increased its stake in RxSight by 6.0% in the 3rd quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company’s stock valued at $193,609,000 after buying an additional 222,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of RxSight by 2.7% in the first quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock valued at $78,634,000 after acquiring an additional 40,500 shares in the last quarter. State Street Corp increased its stake in shares of RxSight by 8.3% during the third quarter. State Street Corp now owns 817,671 shares of the company’s stock worth $40,417,000 after acquiring an additional 62,349 shares during the period. Geode Capital Management LLC raised its holdings in RxSight by 17.7% during the third quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after purchasing an additional 122,775 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its position in RxSight by 74.9% in the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock valued at $42,490,000 after purchasing an additional 302,367 shares during the period. 78.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RXST has been the topic of several recent analyst reports. Stifel Nicolaus dropped their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Oppenheimer dropped their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Jefferies Financial Group assumed coverage on shares of RxSight in a research report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Finally, Wells Fargo & Company reduced their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.